Payment overview · 2025
General Payments
$317.76
13 reported records · 7 companies
Healthcare provider profile · identity verified
Mitul N Dave, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ELLICOTT CITY, MD · NPI 1396833604
Verified facts
What the public records show
CMS Open Payments records show Mitul N Dave, MD received $317.76 in general payments during 2025 across 13 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $110.61 | 34.8% | 4 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $57.28 | 18.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.24 | 13.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.15 | 10.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.26 | 9.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.68 | 7.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.54 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $288.50 | 11 |
| Education | $29.26 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $110.61 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $62.41 | 3 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $57.28 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $44.24 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1121 | 233 |
| Eliquis | Apixaban | 788 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 664 | 125 |
| Gabapentin | Gabapentin | 404 | 83 |
| Trazodone Hcl | Trazodone Hcl | 394 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 383 | 70 |
| Furosemide | Furosemide | 351 | 74 |
| Mirtazapine | Mirtazapine | 346 | 86 |
| Omeprazole | Omeprazole | 318 | 74 |
| Metformin Hcl | Metformin Hcl | 313 | 65 |
| Lisinopril | Lisinopril | 297 | 62 |
| Divalproex Sodium | Divalproex Sodium | 296 | 50 |
| Levetiracetam | Levetiracetam | 291 | 42 |
| Donepezil Hcl | Donepezil Hcl | 289 | 47 |
| Losartan Potassium | Losartan Potassium | 282 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 254 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 250 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 216 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 214 | 45 |
| Carvedilol | Carvedilol | 208 | 39 |
| Memantine Hcl | Memantine Hcl | 173 | 27 |
| Risperidone | Risperidone | 167 | 19 |
| Potassium Chloride | Potassium Chloride | 166 | 33 |
| Baclofen | Baclofen | 157 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 40 |
| Sertraline Hcl | Sertraline Hcl | 150 | 33 |
| Xarelto | Rivaroxaban | 137 | 17 |
| Nifedipine Er | Nifedipine | 118 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 101 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 25 |
| Buspirone Hcl | Buspirone Hcl | 99 | 19 |
| Oxcarbazepine | Oxcarbazepine | 95 | 11 |
| Jardiance | Empagliflozin | 88 | 17 |
| Clonidine Hcl | Clonidine Hcl | 87 | 14 |
| Latanoprost | Latanoprost | 85 | 26 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 81 | suppressed |
| Allopurinol | Allopurinol | 79 | 18 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 76 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 17 |
| Lactulose | Lactulose | 69 | 16 |
| Enulose | Lactulose | 68 | 23 |
| Spironolactone | Spironolactone | 66 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | 15 |
| Trulicity | Dulaglutide | 65 | suppressed |
| Finasteride | Finasteride | 63 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 61 | 61 |
| Tradjenta | Linagliptin | 61 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 12 |
| Simvastatin | Simvastatin | 58 | 13 |
| Olanzapine | Olanzapine | 56 | suppressed |
| Famotidine | Famotidine | 55 | 13 |
| Lidocaine | Lidocaine | 52 | 15 |
| Ozempic | Semaglutide | 52 | 12 |
| Montelukast Sodium | Montelukast Sodium | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Nystatin | Nystatin | 47 | 24 |
| Humalog Kwikpen U-100 | Insulin Lispro | 46 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 28 |
| Lamotrigine | Lamotrigine | 42 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 41 | suppressed |
| Colchicine | Colchicine | 41 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 19 |
| Meloxicam | Meloxicam | 40 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Calcium Acetate | Calcium Acetate | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 12 |
| Timolol Maleate | Timolol Maleate | 33 | suppressed |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Prednisone | Prednisone | 31 | 12 |
| Xifaxan | Rifaximin | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 16 |
| Amantadine | Amantadine Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 28 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 27 | suppressed |
| Brilinta | Ticagrelor | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 15 |
| Cyclosporine | Cyclosporine | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Perphenazine | Perphenazine | 22 | suppressed |
| Phenytoin | Phenytoin | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 14 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $317.76 · 13 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, CAPLYTA, FANAPT, MOUNJARO, REXULTI, ZEPBOUND, bio-ConneKt | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error